Oral PCSK9 for familial hypercholesterolemia

Updates on coffee and AFib, a polypill approach for HFrEF, the first oral PCSK9 inhibitor, vitamin D supplementation for secondary prevention, and more: Joanna Chikwe, MD, chair of the American Heart Association's Scientific Sessions conference and of the Department of Cardiac Surgery in the Smidt Heart Institute at Cedars-Sinai Medical Center, shares clinical research highlights from the recent meeting. Related Content:

• Coffee and AFib, Oral PCSK9 Drugs, an HFrEF Polypill, and Vitamin D Post-MI—Highlights From AHA 2025